UnitedHealthcare Prostate Interventions Coverage Update

Coverage and Medical Necessity Criteria

Transurethral ablation - covered when InterQual criteria met

For medical necessity clinical coverage criteria, refer to InterQual; transurethral ablation is covered when InterQual criteria are met.

Covered indications: Transurethral ablation of the prostate is proven and medically necessary in certain circumstances when medical necessity clinical coverage criteria are met per InterQual CP: Procedures, Prostatectomy; Transurethral Ablation.

Refer to InterQual criteria for detailed inclusion/exclusion

Cryoablation - recurrent prostate cancer

Covered when biopsy-proven recurrent prostate cancer is present.

Covered indication: Cryoablation is proven and medically necessary for recurrent prostate cancer diagnosed by biopsy.

Cryoablation is unproven and not medically necessary for initial treatment of prostate cancer and other indications.

Prostatic urethral lift - FDA-labeled indications

Covered when performed according to FDA-labeled indications, contraindications, warnings, and precautions.

Covered when ALL of the following are met: PUL (prostatic urethral lift) is medically necessary when performed per FDA labeling: patient is >=45 years old with LUTS due to urinary outflow obstruction secondary to BPH (including lateral, with or without median lobe hyperplasia); prostate volume <= 100 cc; no urinary tract infection; no urethral conditions preventing insertion of the delivery system; no current gross hematuria; and no urinary incontinence due to an incompetent sphincter.prostate volume <= 100 cc

Follow FDA labeling and instructions for use

Water vapor thermotherapy - covered per InterQual

Covered when InterQual clinical criteria are met for BPH; not covered for malignant indications.

Covered indications: High-energy water vapor thermotherapy (Rezum) for the treatment of benign prostatic hyperplasia is proven and medically necessary in certain circumstances when InterQual CP: Procedures, Prostatectomy, Transurethral Ablation criteria are met.

Use for malignant prostate tissue and other indications is unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Transurethral water jet ablation - for LUTS due to BPH

Covered for LUTS due to BPH; other indications are unproven.

Covered indication: Transurethral water jet ablation (Aquabeam) is proven and medically necessary for resection and removal of prostate tissue to treat lower urinary tract symptoms due to benign prostatic hyperplasia.

Use for malignant prostate tissue and all other indications is unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Prostate artery embolization - limited indications

Limited coverage for specific clinical scenarios; broader use is unproven.

Covered indications: Prostate artery embolization (PAE) is proven and medically necessary for individuals with BPH who are ineligible for other procedures due to surgical constraints (e.g., prostate size) or anesthesia risk (e.g., comorbidities), and for persistent gross hematuria originating from the prostate.

PAE is unproven and not medically necessary for other indications; evidence shows higher retreatment rates and inferior functional outcomes compared with TURP in some trials—use selective and document contraindication to standard therapies.

Procedures considered unproven / not medically necessary

The following procedures are considered investigational or not medically necessary due to insufficient evidence.

Not medically necessary: The following are unproven and not medically necessary due to insufficient evidence of safety and/or efficacy: insertion of a temporary prostatic urethral stent; transperineal focal laser ablation; transperineal laser ablation (TPLA); transurethral drug-coated balloon dilation (Optilume) when used outside studied or cleared indications; ablation of malignant prostate tissue by magnetic field induction; and transurethral thermal ultrasound ablation (TULSA).

See specific evidence summaries for device- or indication-specific assessments; FDA clearance alone is not a basis for coverage.

Evidence summaries for procedures

Summarized comparative and quality-of-evidence findings that inform coverage decisions.

Cryoablation evidence: Evidence comparing cryoablation to radiation for primary prostate cancer is limited to two small RCTs (307 men) and judged low quality with uncertainty in effects; further research is needed.low-certainty evidence

Cochrane review identified methodological limitations.

Prostatic Urethral Lift (PUL): Noncomparative and randomized evidence suggests symptom improvement up to five years and preservation of sexual function, but limited comparative data trend toward TURP superiority for some outcomes and long-term durability uncertainty remains.limited comparative evidence

Hayes HTA and randomized trials reported durable symptom improvement up to 5 years.

Aquablation (AquaBeam): Randomized trials report IPSS and Qmax improvements similar to TURP up to five years for prostates typically ≤80 mL (some studies include larger prostates); evidence certainty ranges low to moderate with limited long-term comparative data.

PAE coverage considerations

Key considerations from randomized trials and systematic reviews specific to PAE.

PAE evidence summary: Randomized trials and systematic reviews show PAE may provide similar short-term improvement in symptom scores and quality of life compared to TURP but is inferior for many functional outcomes (Qmax, prostate volume reduction) and has higher retreatment rates; adverse events may be fewer but certainty of evidence is low to moderate.

Trials (e.g., Abt et al.) reported ~21% retreatment at 2 years and failed to show non-inferiority for some outcomes; counsel patients accordingly.

TPLA / FLA coverage considerations

Current evidence does not establish long-term effectiveness and safety versus standard surgical options.

TPLA evidence summary: Available randomized trials demonstrate TPLA is inferior to TURP for several efficacy outcomes while showing better preservation of ejaculation; systematic reviews and registries are limited and heterogeneous, and overall evidence is insufficient to support routine use outside clinical trials.

Consider investigational status or use within clinical studies; larger RCTs with longer follow-up are needed.

Transperineal Laser Ablation (TPLA) — evidence and comparative outcomes

Randomized and observational studies report mixed efficacy and short follow-up.

TPLA evidence summary: Small RCTs and prospective series show TPLA may preserve antegrade ejaculation relative to TURP but demonstrate inferior improvements in Qmax and IPSS in some comparative studies; evidence is inconclusive due to small samples and short follow-up.

See Canat et al., Tafuri et al., and ECRI assessment for study-level details.

Temporary urethral stents (iTind) — evidence and outcomes

Evidence for temporary urethral stents (iTind) is limited and mixed.

iTind evidence summary: Randomized, prospective and observational studies report mixed results: an RCT versus sham failed to meet a 3-month primary endpoint (p=0.063) though single-arm and longer-term series report sustained symptom improvements up to 3–4 years; adverse events and loss to follow-up limit certainty.

Evidence insufficient to support routine use compared with established therapies; consider investigational status.

Transurethral drug-coated balloon (Optilume) — evidence and outcomes

Randomized sham-controlled and single-arm studies report clinically meaningful symptomatic and functional improvements, but head-to-head comparative data are lacking.

Optilume efficacy and durability: The randomized PINNACLE trial (double-blind, sham-controlled) and single-arm EVEREST study demonstrated clinically meaningful reductions in IPSS, improved Qmax, and preserved sexual function with sustained improvements through up to four years in single-arm follow-up; however, there are no head-to-head trials versus established surgical therapies.67% responder rate at 2 years in PINNACLE

Prior authorization should document IPSS, Qmax, PVR, prostate size, and prior therapies to match trial populations.

Magnetic nanoparticle ablation and TULSA — experimental/insufficient evidence

Early-phase data show feasibility but important safety and efficacy uncertainties remain.

Magnetic nanoparticle ablation: Phase I data (n=10) demonstrate feasibility but inconsistent intratumoral nanoparticle distribution, treatment-related local toxicity including grade 3 urinary toxicity in some patients, and difficulty achieving adequate heating; evidence insufficient for routine clinical use.

Further research required.

TULSA studies are small, single-arm, and lack comparator groups; evidence is insufficient regarding long-term oncologic outcomes, safety, and comparative effectiveness to standard treatments.

Guidelines advise against routine use outside clinical trials.

TULSA — evidence‑based coverage considerations

Guideline statements and evidence limitations should guide coverage decisions for TULSA.

TULSA coverage considerations: Coverage decisions should account for limited evidence on long-term oncologic outcomes, small single-arm study designs, and guideline recommendations that focal or whole-gland ablation not be routinely recommended outside clinical trials; informed shared decision-making and enrollment in trials are preferred.

Monitor emerging comparative studies before broad coverage.

Optilume urethral drug‑coated balloon — evidence summary

Device clearance and single-arm follow-up inform coverage posture; absence of comparative trials limits conclusions.

Optilume evidence considerations: Single-arm study follow-up (original N=80, 59 at 4-year follow-up) showed sustained symptom improvement and preserved sexual function with most adverse events occurring within three months; Optilume received FDA PMA clearance—coverage should align with device indication and available long-term data versus alternative therapies.

Limitations include single-arm design and lack of head-to-head comparisons.

Guideline‑driven coverage principles for minimally invasive BPH and focal prostate treatments

Clinical guidelines provide condition-specific recommendations that should inform coverage decisions.

Guideline recommendations: AUA guidelines: PUL and water vapor therapy may be offered for selected prostate sizes and when preservation of sexual function is desired; temporary implanted prostatic devices may be offered for specified prostate volumes; PAE may be offered when performed by trained clinicians. AUA/ASTRO guidelines: clinicians should discuss standard options for favorable intermediate-risk prostate cancer and advise that ablation procedures not be recommended outside clinical trials. NCCN: local ablation options are not recommended as routine primary therapy due to lack of long-term comparative data.

Use guideline-specified prostate volume ranges and conditional recommendations when applying coverage criteria.

Coverage revisions and stances

Policy revisions and clarifications relevant to coverage applications.

Prostatic urethral lift coverage revision: Coverage criteria were revised to allow treatment of urinary outflow obstruction secondary to BPH, including lateral, with or without median lobe hyperplasia, in men 45 years of age or older.

Replaced prior requirement that specified both lateral and median lobe hyperplasia.

Transurethral water jet ablation stance: Transurethral water jet ablation for treatment of malignant prostate tissue and all other indications not listed as proven is unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Clarifies scope of unproven indications.

Prostate artery embolization (PAE) wording change: Wording clarified that PAE is proven and medically necessary for individuals with BPH who are ineligible for other procedures due to surgical constraints or anesthesia risk.

Replaces less specific prior phrasing.

Several procedures and indications addressed in this policy are explicitly classified as unproven and not medically necessary because the available literature does not demonstrate sufficient evidence of safety and/or effectiveness. Examples include certain uses of transurethral ablation outside established indications, water vapor or water jet therapies when applied to malignant prostate tissue, and a range of emerging implant and focal‑therapy technologies. Coverage requests for these indications carry a heightened risk of denial unless robust supporting evidence or trial enrollment is documented.

A targeted literature search did not identify peer‑reviewed original data supporting the use of high‑energy water vapor thermotherapy for ablation of malignant prostate tissue. While the technology is established for selected benign prostatic hyperplasia (BPH) indications per InterQual, use for malignant tissue is specifically noted as unproven and not medically necessary due to absence of published evidence on oncologic safety or efficacy.

Routine use of focal therapy (including focal laser ablation / transperineal laser ablation) for localized prostate cancer is not recommended. Systematic reviews and guideline statements note limited, heterogeneous data and lack of high‑quality comparative evidence; AUA/ASTRO guidance advises that focal or whole‑gland ablation should not be offered outside clinical trials or prospective comparative studies. Consequently, focal ablation as routine primary therapy is considered not medically necessary in the absence of trial participation or clear comparative data.

Ablation of malignant prostate tissue using magnetic field induction (nanoparticle‑mediated heating) and TULSA (transurethral thermal ultrasound ablation) is considered investigational. Available reports are limited to early phase or single‑arm series, show technical challenges and some serious local toxicities, and lack robust comparative or long‑term oncologic outcomes; therefore these approaches are unproven and not medically necessary for routine oncologic treatment.

Clinical practice guidelines emphasize caution for prostate ablation procedures: for patients with localized prostate cancer clinicians should discuss standard options (active surveillance, radiation, radical prostatectomy) and be aware that guideline panels advise against recommending whole‑gland or focal ablation outside of clinical trials. This policy aligns with those guideline recommendations and restricts routine coverage of ablative procedures for oncologic indications to trial settings or carefully documented investigational use.

Device regulatory status is informational only: an FDA clearance or approval of a device does not, by itself, establish medical necessity or constitute automatic coverage. The policy explicitly states that FDA marketing authorization for devices used in prostate procedures is not alone a basis for coverage, and coverage determinations are driven by clinical evidence and benefit plan terms.

Procedures listed in this policy as unproven and not medically necessary include: insertion of a temporary prostatic urethral stent; transperineal focal laser ablation; transperineal laser ablation (TPLA); transurethral drug‑coated balloon dilation; ablation of malignant prostate tissue by magnetic field induction; and transurethral thermal ultrasound ablation (TULSA). Additionally, transurethral water jet ablation and high‑energy water vapor thermotherapy are not considered medically necessary when used to treat malignant prostate tissue or for indications not otherwise specified as proven in the policy.

Several procedures lack adequate comparative or long‑term evidence to support routine use. For example, cryoablation trials versus radiation are few, small, and judged to be of low‑quality evidence; TPLA randomized trials demonstrate inferior efficacy to TURP despite better sexual outcomes; and temporary urethral stents are supported mainly by limited RCTs and noncomparative series. These evidence gaps underpin the policy stance that such procedures are investigational or not medically necessary for general use.

Although prostate artery embolization (PAE) can provide short‑term symptom improvement and may have favorable perioperative safety and sexual function profiles, systematic reviews and randomized trials indicate inferior performance for several functional outcomes (e.g., Qmax, prostate volume reduction) and a higher retreatment rate compared with TURP. Given these limitations and low‑to‑moderate certainty of the evidence, PAE is considered investigational for general use unless the patient is ineligible for other surgical procedures or has documented anesthesia risk, in which case PAE may be considered medically necessary.

Temporary urethral stents (including iTind and similar devices) lack high‑quality, long‑term comparative evidence demonstrating sustained efficacy and safety versus established therapies. Randomized and observational studies show mixed results, risk of loss to follow‑up, and limited applicability to patients with larger prostates or complex anatomy; therefore use of temporary urethral stents is considered unproven and not medically necessary outside of well‑designed clinical studies.

Oncologic ablation procedures (whole‑gland or focal) for prostate cancer lack high‑quality comparative evidence demonstrating equivalent cancer control compared with standard definitive therapies (radiation or radical prostatectomy). Systematic reviews and randomized data are limited and heterogeneous, and guideline panels advise that such procedures should not be routine primary therapy. Accordingly, most oncologic ablation indications are judged not medically necessary outside of research settings.

This policy explicitly names TULSA and transurethral water jet ablation for malignant prostate tissue among procedures considered unproven and not medically necessary. The TULSA literature consists principally of small, single‑arm studies with limited follow‑up and no strong comparative oncologic outcomes; magnetic nanoparticle and other novel ablative techniques likewise have insufficient evidence to support routine clinical use for malignancy.

Applicable Procedure and Device Codes

Applicable procedure codes (CPT/Category III/misc)mixed

0421T	Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete
0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance
0619T	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound
0714T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume less than 50 mL
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring; thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation
0867T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50 mL
37243	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural road mapping; and imaging guidance necessary to complete the intervention: for tumors, organ ischemia, or infarction (when performed on prostate tissue)
51721	Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation, including suprapubic tube placement during the same session and placement of an endorectal cooling device, when performed

1–10 of 21

1/3

Procedures and devices discussed (no specific codes listed in this section)mixed

No codes listed

Device regulatory statuses and product codesmixed

510(k)	FDA clearance pathway referenced for multiple devices (UroLift, Rezum, Aquabeam, laser devices, high intensity ultrasound systems)
PMA	FDA premarket approval pathway referenced for Optilume Urethral Drug Coated Balloon
Product code PLP	FDA product code referenced for high intensity ultrasound ablation systems
Product code NOY	FDA product code referenced for microsphere products for treatment of BPH

Policy-code changesCPT

51721	CPT code added (as listed in policy changes)
53865	CPT code added (as listed in policy changes)
53866	CPT code added (as listed in policy changes)
55881	CPT code added (as listed in policy changes)
55882	CPT code added (as listed in policy changes)
55874	CPT code removed (as listed in policy changes)

Prostate volume (policy thresholds referencing code descriptors)

PUL prostate size limitProstatic urethral lift is indicated when prostate volume ≤100 cc; prostate volume >100 cc is excluded.

CPT code volume thresholds (0714T)Code 0714T describes transperineal laser ablation for BPH with prostate volume <50 mL.

CPT code volume thresholds (0867T)Code 0867T describes transperineal laser ablation for BPH with prostate volume ≥50 mL.

Prostate volume ranges reported in trials

Aquablation trial range (typical)Most aquablation studies include prostate volumes in the range of 20–80 mL; some trials and series include larger prostates up to 150 mL (e.g., WATER II mean 107 cc).

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is required for prostate artery embolization (PAE) and is generally required for newer or less established device-based prostate procedures (for example, transurethral drug‑coated balloon dilation, TULSA, transperineal laser ablation, temporary urethral stents) per plan medical necessity rules and when InterQual or FDA‑based criteria apply. Submit clinical documentation demonstrating indication, prior conservative therapies tried (when applicable), and patient selection rationale.

Prior authorization required for PAE (see InterQual/FDA criteria).
Prior authorization recommended/likely required for transurethral drug‑coated balloon, TULSA, transperineal laser ablation (TPLA), temporary urethral stents, and other device‑based procedures.
Prior authorization reviewers will reference InterQual criteria and applicable FDA labeled indications; FDA clearance alone does not guarantee coverage.

Documentation Required

Informed Consent and Selection Documentation

Document informed consent and shared decision‑making for PAE and other newer procedures, including discussion of alternative established therapies (medical therapy, TURP, laser enucleation, PUL, water vapor or waterjet therapies), expected benefits, risks, and higher retreatment rates observed with some novel procedures.

Clinical Background and Scope

Benign prostatic hyperplasia (BPH) is common in men older than 50 and can cause lower urinary tract symptoms (LUTS) and urinary retention. Initial management typically includes lifestyle modification and medical therapy; minimally invasive and surgical procedures are considered when conservative measures fail or are not tolerated. The policy evaluates multiple device‑based and ablative approaches intended to reduce prostate volume or relieve obstruction and places emphasis on comparative evidence, durability of benefit, and safety.

Definitions and Device/Procedure Descriptions

Cryoablation definition

DefinitionCryoablation (cryosurgery/cryotherapy) uses transrectal ultrasound‑guided perineal probes through which very cold gas is passed to freeze and destroy prostate tissue.

Typical useProstate cryoablation is described as used for recurrent prostate cancer and investigated for primary treatment, per descriptive text.

Guidance techniqueProcedure is performed with transrectal ultrasound guidance for probe placement and monitoring.

Prostatic urethral lift (PUL) definition

DefinitionProstatic urethral lift (PUL) places permanent UroLift implants to hold open the lateral and median lobes of the prostate to reduce urinary obstruction from BPH.

FDA clearance noteUroLift System cleared by FDA (510(k)) for treatment of outflow obstruction secondary to BPH, including lateral and median lobe hyperplasia in men 45+.

Policy Update Changes

2025-08-01policy_revisionLatest

Removed coverage criteria for transperineal placement of biodegradable material; revised Prostatic Urethral Lift criteria to allow 'lateral, with or without median lobe hyperplasia' rather than requiring both; clarified Transurethral Water Jet Ablation is unproven and not medically necessary for malignant prostate tissue and other non‑proven indications; clarified PAE wording to specify individuals with BPH; added Transurethral Thermal Ultrasound Ablation (TULSA) to the list of unproven procedures; added CPT codes 51721, 53865, 53866, 55881, and 55882 and removed CPT code 55874 (noting some added codes are not on the Louisiana Medicaid Fee Schedule).

OpenPayer

Prostate Surgeries and Interventions (for Louisiana Only)